Skip to main content

Table 3 Coverage survey results

From: Rapid ethnography and participatory techniques increase onchocerciasis mass drug administration treatment coverage in Benin: a difference-in-differences analysis

 

Intervention n (%)

Control n (%)

Total n (%)

Total households

N = 1228

N = 1209

N = 2437

Total individuals

N = 8547

N = 6028

N = 14,575

Household visited by a CDD during MDA

1020 (83.1%)

709 (58.6%)

1729 (70.9%)

Home marked by CDDa

910 (74.1%)

364 (30.1%)

1274 (52.3%)

Marking observed by study team

869 (70.8%)

239 (19.8%)

1108 (45.5%)

Knew about MDA in advance

1005 (81.8%)

656 (54.3%)

1661 (68.2%)

 From friend/familyb

232 (23.1%)

299 (45.6%)

531 (32.0%)

 From health personnelb

45 (4.48%)

88 (13.4%)

133 (8.01%)

 From CDDb

128 (12.7%)

130 (19.8%)

258 (15.5%)

 From community or religious leaderb

108 (10.7%)

97 (14.8%)

205 (12.3%)

 From radiob

701 (69.8%)

215 (32.8%)

916 (55.1%)

 From social networksb

11 (1.09%)

10 (1.52%)

21 (1.26%)

 Other sourcesb

79 (7.86%)

35 (5.34%)

114 (6.86%)

 Do not knowb

15 (1.49%)

10 (1.52%)

25 (1.51%)

Offered ivermectin at home or in the communityc

6118 (71.7%)

3160 (52.5%)

9278 (63.8%)

Reasons why ivermectin was not offerredd

   

 CDD did not come to home

895 (38.3%)

1843 (66.7%)

2738 (53.7%)

 Individual was not eligible for treatment

860 (36.8%)

446 (16.1%)

1306 (25.6%)

 Not home during MDA

466 (19.9%)

409 (14.8%)

857 (17.2%)

 Had not heard about MDA in advance

108 (4.62%)

202 (7.31%)

310 (6.08%)

 Drug stock was exhausted

86 (3.68%)

36 (1.30%)

122 (2.39%)

 Other

24 (1.03%)

15 (0.54%)

29 (0.76%)

Consumed ivermectine

5892 (96.3%)

3052 (96.6%)

8944 (96.4%)

Directly observed treatmentf

4920 (83.5%)

2261 (74.1%)

7181 (80.3%)

Reasons why ivermectin was not consumedg

   

 Fear of side effects

24 (13.3%)

16 (25.0%)

40 (16.3%)

 Bad taste

1 (0.55%)

9 (14.1%)

10 (4.08%)

 Not sick, don’t need treatment

9 (4.97%)

7 (10.9%)

16 (6.53%)

 Not enough information from CDDs

16 (8.84%)

3 (4.69%)

19 (7.76%)

 The medicine does not work

0 (0%)

2 (3.13%)

2 (0.816%)

 Not concerned by disease

66 (36.5%)

26 (40.6%)

92 (37.6%)

 Otherh

70 (38.7%)

8 (12.5%)

78 (31.8%)

 Remember taking MDA in 2019i

3472 (50.8%)

2383 (49.9%)

5855 (50.4%)

  1. aAmongst all households visited
  2. bAmongst those who were aware MDA would take place before CDDs arrived
  3. cAmongst all individuals surveyed
  4. dAmongst individuals reporting that they were not offered ivermectin
  5. eAmongst individuals offered ivermectin
  6. fAmongst individuals reporting that they swallowed ivermectin
  7. gAmongst individuals who refused to take the treatment when offered
  8. hWhile responses to “other” were diverse, many respondents answering with “other” indicated that they did not take the treatment when offered because they did not believe that they were eligible and should not have been offered treatment to begin with (ex. they were sick, pregnant, etc.)
  9. iAmongst individuals present to answer without proxy
Back to article page

Implementation Science Communications

ISSN: 2662-2211